REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
21 hedge funds and large institutions have $39.5M invested in REVIVA PHARMA HLDGS INC in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
15% more capital invested
Capital invested by funds: $34.4M → $39.5M (+$5.13M)
5.23% more ownership
Funds ownership: 41.28% → 46.51% (+5.2%)
5% more funds holding
Funds holding: 20 → 21 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.37M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$2.65M |
| 3 |
CI
Cowen Inc
New York
|
+$1.43M |
| 4 |
MSU
Mizuho Securities USA
New York
|
+$1.29M |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$512K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$2.42M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$755K |
| 3 |
Walleye Trading
New York
|
-$745K |
| 4 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$675K |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$255K |
RVPH Hedge Fund Activity: Q2 2019 in Review
21 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q2 2019, worth a combined $39.5M — up 15% from $34.4M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new RVPH positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $3.37M. The largest seller was Weiss Asset Management, cutting an estimated $2.42M.
- 21 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q2 2019, up from 20 in Q1 2019.
- Funds reported $39.5M of REVIVA PHARMA HLDGS INC stock for Q2 2019, up 15% quarter-over-quarter.
- 2 funds opened new REVIVA PHARMA HLDGS INC positions in Q2 2019 and 1 closed out, a net change of +1 holder.
- The largest REVIVA PHARMA HLDGS INC buyer in Q2 2019 was Bank of America, an estimated $3.37M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q2 2019 was Weiss Asset Management, an estimated $2.42M sold.
Based on aggregated 13F filings for Q2 2019.